Gelesis announces FDA approval for prescription drug PLENITY

obesity is a disease that increases the risk of more than 30 diseases, such as diabetes, non-alcoholic fatty liver disease (NAFLD)According to the survey, 70 to 80 percent of obese patients have NAFLD and 85 percent of people with type 2 diabetes have symptoms of being overweight or obeserecently, Gelesis(http://announced that its prescription drug, THE GELesis 100, had approved thethe FDA(http://ABOUT PLENITYPLENITY IS AN ORAL OVER-THE-COUNTER DRUG THAT CAN BE USED AS AN UNSYSTEMATIC WEIGHT MANAGEMENT AIDThedrug(http://consists of modified cellulose and citric acid, which form a three-colorThis matrix quickly absorbs moisture from the stomach and blends evenly with the food ingested, resulting in thousands of small, single gel blocksthese gel blocks have the elasticity or hardness of the food, but do not have a calorie value, can occupy the stomach and small intestine contents of the space, and cause a feeling of satietyOnce the gel block enters the large intestine, it is partially broken down by the enzyme, losing the three-dimensional structure, thus losing most of the absorption capacityThe water released with decomposition is reabsorbed by the large intestine, and the remaining cellulose material is discharged into the fecesALTHOUGH IT NEEDS TO BE TAKEN ORALLY, PLENITY IS CERTIFIED AS A
MEDICAL DEVICE
(HTTP://WWW.CHEMDRUG.COM/INVEST/253/)
DUE TO ITS UNIQUE
MODE OF
MECHANICAL
(HTTP://WWW.CHEMDRUG.COM/SELL/22/) 　　CURRENTLY, PLENITY HAS CONDUCTED CRITICAL STUDIES SUCH AS HYPERCENTER, DOUBLE-BLIND, AND PLACEBO CONTROL, ASSESSING THE WEIGHT COMPARISONS OF 436 OVERWEIGHT OR OBESE ADULTS AFTER SIX MONTHS OF TREATMENT Ninety-four percent of patients lost more than 5 percent of their body weight after taking PLENITY, and 26 percent of them were "super-reflectors" of PLENITY, losing an average of 14 percent (about 30 pounds) it is worth noting that the most common side effects of taking the drug are gastrointestinal diseases such as bloating, abdominal pain, diarrhea, constipation, and gastrointestinal bloating, followed by infections and musculoskeletal connective tissue diseases 　　Gelesis launched the U.S Targeted PLENITY launch program in the second half of 2019, and ISEXPECTS THAT PLENITY WILL BE WIDELY AVAILABLE IN THE U.S BY 2020